News & Analysis as of

Motion To Stay Pharmaceutical Patents Sanofi

Goodwin

Litigation Update: Sanofi’s Summary Judgment Motion Denied, Immunex Renews Its Motion to Stay Pending IPR in Dupixent® Patent...

Goodwin on

Following up on our previous coverage of Immunex’s patent infringement suit against Sanofi related to Immunex’s Dupixent® (dupilumab) biologic, Judge Otero recently denied Sanofi’s motion for summary judgement of invalidity...more

Goodwin

Immunex Files Reply In Support of Motion To Stay Dupixent® Patent Litigation

Goodwin on

In the ongoing Immunex v. Sanofi patent litigation regarding Immunex’s claims of infringement against Sanofi and Regeneron’s Dupixent® (dupilumab) product, Immunex has filed a reply brief in support of its motion to stay the...more

Goodwin

Immunex Moves To Stay Dupixent® Patent Litigation Pending IPR

Goodwin on

Last week, in the ongoing Immunex v. Sanofi patent litigation regarding Immunex’s claims of infringement against Sanofi and Regeneron’s Dupixent® (dupilumab) product, Immunex moved to stay the litigation pending resolution of...more

3 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide